Cellares and Sonoma Biotherapeutics have announced a strategic collaboration to automate the manufacturing of a novel cell therapy for autoimmune diseases. This partnership will leverage Cellares' advanced manufacturing platform to produce SonomaBio's lead candidate, SBT-77-7101, for rheumatoid arthritis. The agreement marks a significant step toward scaling the production of complex regulatory T cell (Treg) therapies, potentially making them more accessible for patients with severe conditions.
Automating a Complex Therapy
The collaboration centers on transferring SonomaBio’s proprietary manufacturing process for SBT-77-7101 onto the Cellares Cell Shuttle. This automated platform is designed to handle the intricate and sensitive processes required for producing Treg cell therapies. By automating both manufacturing and quality control through its Cell Q™ system, Cellares aims to overcome the labor-intensive challenges that typically hinder the large-scale production of these specialized cells.
Regulatory T cells are notoriously difficult to manufacture reliably while preserving their unique identity and therapeutic function. Stephen Dilly, CEO of Sonoma Biotherapeutics, emphasized that the precision of their process is crucial for the therapy's effectiveness. This partnership combines SonomaBio's deep expertise in Treg biology with Cellares' automated infrastructure to ensure consistent, high-quality production for late-stage clinical trials and eventual commercialization.
A Novel Approach for Rheumatoid Arthritis
SonomaBio's SBT-77-7101 is an autologous CAR-Treg cell therapy currently in Phase 1 clinical development. It is specifically designed for patients with poly-refractory rheumatoid arthritis, a group that has exhausted all other available treatment options. This program represents the first Treg cell therapy to be onboarded to the Cell Shuttle, extending the platform's capabilities into a new and demanding therapeutic modality.
The therapy works by engineering a patient's own regulatory T cells to restore balance to the immune system, thereby treating the underlying cause of the autoimmune disease. Founded by pioneers in the field, Sonoma Biotherapeutics is at the forefront of developing this new generation of targeted and durable cell therapies. The company's work is built on foundational Treg research, aiming to provide new hope for those with serious inflammatory conditions.
Strategic Scaling and Global Reach
Cellares operates as the first Integrated Development and Manufacturing Organization (IDMO), offering an end-to-end solution for cell therapy production. The company's IDMO Smart Factory in Bridgewater, New Jersey, provides commercial-scale capacity, with additional facilities planned for Europe and Japan. This global manufacturing network is designed to support partners from early clinical phases through to full commercial launch, ensuring a reliable supply chain.
Fabian Gerlinghaus, CEO of Cellares, noted the significance of adapting the platform for Tregs, one of the most technically demanding cell types. He highlighted that the Cell Shuttle has already been validated for CAR-T therapies and has received the FDA's Advanced Manufacturing Technology designation. This collaboration with SonomaBio demonstrates the platform's versatility and its potential to industrialize the production of life-saving therapies across different modalities.
In conclusion, the partnership between Cellares and Sonoma Biotherapeutics represents a pivotal advancement in the field of regenerative medicine. By combining SonomaBio's innovative Treg therapy with Cellares' automated manufacturing technology, the collaboration aims to solve critical production bottlenecks. This strategic alliance not only accelerates the development of a promising treatment for severe rheumatoid arthritis but also sets a new standard for manufacturing next-generation cell therapies at scale.